Skip to main content
Erschienen in: Netherlands Heart Journal 4/2021

Open Access 11.03.2021 | Letter to the Editor

Reply to the letter of Groenveld et al.: ‘Routine measurement of oesophageal temperature during cryoballoon pulmonary vein isolation’

verfasst von: J. M. van Opstal, Y. J. Stevenhagen, P. F. H. M. van Dessel, M. F. Scholten

Erschienen in: Netherlands Heart Journal | Ausgabe 4/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
To the Editor,
We would like to thank Groenveld et al. for this opportunity to discuss the results of our study regarding the high incidence of (ultra)low oesophageal temperatures during cryoballoon pulmonary vein isolation (PVI) and our recommendation to routinely measure oesophageal temperatures to avoid atrio-oesophageal complications during PVI [1]. Groenveld et al. suggest that routine oesophageal temperature measurement during PVI is unnecessary as the incidence of atrio-oesophageal fistula is low and most oesophageal lesions are asymptomatic. Furthermore, they argue that measurement of oesophageal temperatures cannot prevent oesophageal lesions [2, 3].
Although the incidence of atrio-oesophageal fistula is low, it is often a deadly complication of treatment for a nonfatal arrhythmia. Furthermore, the incidence of gastroparesis and hypomotility (caused by damage to the branches of the vagal nerve surrounding the oesophagus) is much higher (up to 17%) [4]. As such, oesophageal lesions should be avoided as they are most likely the precursor of these dreadful complications.
In line with this, the 2017 Heart Rhythm Society/European Heart Rhythm Association expert consensus statement on catheter and surgical ablation of atrial fibrillation states it is reasonable to use an oesophageal temperature probe during ablation procedures to monitor oesophageal temperatures to help guide energy delivery (Class IIa) [5]. Luminal oesophageal temperature—guided PVI significantly reduces the incidence of thermal oesophageal lesions [6]. Moreover, although lesions cannot always be avoided, they tend to be smaller in patients when using a temperature probe [7].
The most probable reason that oesophageal lesions are still present despite measurement of luminal oesophageal temperatures is that current temperature probes do not provide adequate coverage of the oesophageal width. As a result, the temperature of the oesophageal tissue at risk—situated closest to the posterior wall of the left atrium—is not always sufficiently monitored.
Therefore, further research and development in this field is necessary to eliminate PVI-related atrio-oesophageal complications. Until that time, we have to use the oesophageal thermoprobes at our disposal, bearing in mind Hippocrates’s phrase primum non nocere (first, do no harm).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Molenaar MMD, Hesselink T, Scholten MF, et al. High incidence of (ultra)low oesophageal temperatures during cryoballoon pulmonary vein isolation for atrial fibrillation. Neth Heart J. 2020;28:662–9.CrossRef Molenaar MMD, Hesselink T, Scholten MF, et al. High incidence of (ultra)low oesophageal temperatures during cryoballoon pulmonary vein isolation for atrial fibrillation. Neth Heart J. 2020;28:662–9.CrossRef
2.
Zurück zum Zitat Ha FJ, Han HC, Sanders P, et al. Prevalence and prevention of oesophageal injury during atrial fibrillation ablation: a systematic review and meta-analysis. Europace. 2019;21:80–90.CrossRef Ha FJ, Han HC, Sanders P, et al. Prevalence and prevention of oesophageal injury during atrial fibrillation ablation: a systematic review and meta-analysis. Europace. 2019;21:80–90.CrossRef
3.
Zurück zum Zitat Schoene K, Arya A, Grashoff F, et al. Oesophageal probe evaluation in radiofrequency ablation of atrial fibrillation (OPERA): results from a prospective randomized trial. Europace. 2020;22:1487–94.CrossRef Schoene K, Arya A, Grashoff F, et al. Oesophageal probe evaluation in radiofrequency ablation of atrial fibrillation (OPERA): results from a prospective randomized trial. Europace. 2020;22:1487–94.CrossRef
4.
Zurück zum Zitat Miyazaki S, Taniguchi H, Kusa S, et al. Factors associated with periesophageal vagal nerve injury after pulmonary vein antrum isolation. J Am Heart Assoc. 2014;3:e1209.CrossRef Miyazaki S, Taniguchi H, Kusa S, et al. Factors associated with periesophageal vagal nerve injury after pulmonary vein antrum isolation. J Am Heart Assoc. 2014;3:e1209.CrossRef
5.
Zurück zum Zitat Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace. 2018;20:157–208.CrossRef Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Europace. 2018;20:157–208.CrossRef
6.
Zurück zum Zitat Fürnkranz A, Bordignon S, Böhmig M, et al. Reduced incidence of esophageal lesions by luminal esophageal temperature-guided second-generation cryoballoon ablation. Heart Rhythm. 2015;12:268–74.CrossRef Fürnkranz A, Bordignon S, Böhmig M, et al. Reduced incidence of esophageal lesions by luminal esophageal temperature-guided second-generation cryoballoon ablation. Heart Rhythm. 2015;12:268–74.CrossRef
7.
Zurück zum Zitat Halbfass P, Müller P, Nentwich K, et al. Incidence of asymptomatic oesophageal lesions after atrial fibrillation ablation using an oesophageal temperature probe with insulated thermocouples: a comparative controlled study. Europace. 2017;19:385–91.PubMed Halbfass P, Müller P, Nentwich K, et al. Incidence of asymptomatic oesophageal lesions after atrial fibrillation ablation using an oesophageal temperature probe with insulated thermocouples: a comparative controlled study. Europace. 2017;19:385–91.PubMed
Metadaten
Titel
Reply to the letter of Groenveld et al.: ‘Routine measurement of oesophageal temperature during cryoballoon pulmonary vein isolation’
verfasst von
J. M. van Opstal
Y. J. Stevenhagen
P. F. H. M. van Dessel
M. F. Scholten
Publikationsdatum
11.03.2021
Verlag
Bohn Stafleu van Loghum
Erschienen in
Netherlands Heart Journal / Ausgabe 4/2021
Print ISSN: 1568-5888
Elektronische ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-021-01558-7

Weitere Artikel der Ausgabe 4/2021

Netherlands Heart Journal 4/2021 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.